Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin for the year ending March 31, 2024: 24.40%

Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin is 24.40% for the year ending March 31, 2024, a -9.43% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin for the year ending March 31, 2023 was 26.94%, a -0.21% change year over year.
Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin for the year ending March 31, 2022 was 26.99%, a -5.79% change year over year.
Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin for the year ending March 31, 2021 was 28.65%, a 4.98% change year over year.
Fuso Pharmaceutical Industries,Ltd. Gross Profit Margin for the year ending March 31, 2020 was 27.29%, a -6.36% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years